Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARC-AAT in Alpha-1 Antitrypsin Deficiency
NCT02363946Phase 1Terminated
- Sponsor
- Arrowhead Pharmaceuticals
- Start
- Feb 2015
- Primary completion
- Nov 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 4
01
Overview
Phase 1, randomised, double-blind trial of ARC-AAT in alpha-1 antitrypsin deficiency (AATD) (15 arms), sponsored by Arrowhead Pharmaceuticals. Primary endpoints: Treatment-Emergent Adverse Events at 29 days, Clinically Significant Treatment-Emergent Abnormalities in Laboratory Values at 29 days and 8 more. Started Feb 2015; status: terminated.
02
Drugs
ARC-AAT
03
Conditions
alpha-1 antitrypsin deficiency (AATD)
Beyond the preview
Go deeper on NCT02363946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02363946.